Enzalutamide‐induced severe thrombocytopenia complicated by a seizure in a 76‐year‐old man with castration‐resistant prostate cancer
Authors:
Open Access
- 31 October 2018
- journal article
- case report
- Published by Wiley in IJU Case Reports
- Vol. 2 (1) , 9-11
Abstract
Introduction: Adverse events with enzalutamide widely used for men with castration‐resistant prostate cancer are of interest.Case presentation: A 76‐year‐old man developed castration‐resistant prostate cancer. He received 160 mg of enzalutamide daily. On the 13th day after treatment, severe thrombocytopenia was observed (platelet count: 1.9 × 104/μL). Normal coagulation and fibrinolytic systems suggested thrombocytopenia induced by enzalutamide. Enzalutamide was withdrawn immediately, and platelet count uneventfully recovered to 7.0 × 104/μL and 28.8 × 104/μL 9 and 30 days after discontinuation, respectively. He restarted enzalutamide therapy without thrombocytopenia recurrence. However, 81 days after restarting enzalutamide, he experienced a seizure. There were no significant findings from brain computed tomography, which suggested that the seizure was also an enzalutamide‐associated adverse event.Conclusion: Thrombocytopenia may occur early following enzalutamide therapy, and blood analysis within 2 weeks after treatment may facilitate its management. Enzalutamide‐induced thrombocytopenia, complicated by seizure, has not been reported.Keywords
This publication has 9 references indexed in Scilit:
- Continuous use of enzalutamide in a patient who developed enzalutamide-induced thrombocytopeniaBMJ Case Reports, 2015
- Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with DegarelixCase Reports in Oncological Medicine, 2015
- U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerThe Oncologist, 2015
- An update on enzalutamide in the treatment of prostate cancerTherapeutic Advances in Urology, 2014
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyNew England Journal of Medicine, 2014
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Drug-Induced Immune ThrombocytopeniaNew England Journal of Medicine, 2007
- Disseminated Intravascular Coagulation as the Presenting Sign of Metastatic Prostate CancerJournal of General Internal Medicine, 2006